Research programme: cancer biotherapeutics - Zymeworks

Drug Profile

Research programme: cancer biotherapeutics - Zymeworks

Alternative Names: Bispecific ADCs - Zymeworks; Checkpoint Modulating Bispecifics - Zymeworks; T Cell Engaging Bispecifics - Zymeworks

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates
  • Mechanism of Action Immunomodulators; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 15 Jun 2017 Preclinical trials in Solid tumours in Canada (Parenteral) before June 2017 (Zymeworks pipeline, June 2017)
  • 22 Mar 2016 Kairos Therapeutics has been acquired by Zymeworks
  • 08 Jan 2016 Kairos Therapeutics and Zymeworks enter into an agreement to develop Cancer biotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top